Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Podobne zapisy

• Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: A randomized controlled trial in Papua New Guinea
  od: van den Biggelaar, Anita. H.J., i wsp.
  Wydane: (2009)
• Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
  od: Pomat, William S., i wsp.
  Wydane: (2013)
• Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children
  od: Orami, Tilda, i wsp.
  Wydane: (2020)
• Maternal Antibodies to Pneumolysin but Not to Pneumococcal Surface Protein A Delay Early Pneumococcal Carriage in High-Risk Papua New Guinean Infants
  od: Francis, Jacinta P., i wsp.
  Wydane: (2009)
• Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
  od: van den Biggelaar, Anita H. J., i wsp.
  Wydane: (2017)